Vikas EcoTech Limited — Interim / Quarterly Report 2022

Nov 14, 2022

==> picture [465 x 84] intentionally omitted <==

November 14, 2022

Listing Compliance Department Listing Compliance Department National Stock Exchange of India Limited. BSE Limited. Exchange Plaza, Bandra-Kurla Complex, Phirozee Jeejeebhoy Towers, Bandra (E), Mumbai 400051 Dalal Street, Fort, Fax: 022-26598235/36 Mumbai - 400 001 NSE Symbol: VIKASECO Scrip Code: 530961

" Subject: Newspaper Advertisement- Second and Final Reminder Cum Forfeiture Notice” for First and Final Call Money

The Company has published an advertisement on November 14, 2022 in connection with the issue of Second and Final Reminder Cum Forfeiture Notice for Payment of First and Final Call Money in the following newspapers:

(i) Business Standard (English newspaper); and

(ii) Business Standard (Hindi newspaper)

Copies of the newspaper advertisement so published are enclosed herewith. The same are also available on the website of the Company at www.vikasecotech.com.

This disclosure is being made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take the information on record and oblige.

Thanking you, Yours Faithfully,

for Vikas Ecotech Limited

Digitally DINESH signed by BHARDWAJ DINESH BHARDWAJ Dinesh Bhardwaj CEO & Whole Time Director DIN: 07719674

13

NEW DELHI | MONDAY, 14 NOVEMBER 2022

~~>~~

SHIVA MILLS LIMITED Regd. Office : 252, METTUPALAYAM ROAD, COIMBATORE 641 043 CIN : L17111TZ2015PLC022007 Website : www.shivamills.com	SHIVA MILLS LIMITED Regd. Office : 252, METTUPALAYAM ROAD, COIMBATORE 641 043 CIN : L17111TZ2015PLC022007 Website : www.shivamills.com	SHIVA MILLS LIMITED Regd. Office : 252, METTUPALAYAM ROAD, COIMBATORE 641 043 CIN : L17111TZ2015PLC022007 Website : www.shivamills.com	SHIVA MILLS LIMITED Regd. Office : 252, METTUPALAYAM ROAD, COIMBATORE 641 043 CIN : L17111TZ2015PLC022007 Website : www.shivamills.com	SHIVA MILLS LIMITED Regd. Office : 252, METTUPALAYAM ROAD, COIMBATORE 641 043 CIN : L17111TZ2015PLC022007 Website : www.shivamills.com	SHIVA MILLS LIMITED Regd. Office : 252, METTUPALAYAM ROAD, COIMBATORE 641 043 CIN : L17111TZ2015PLC022007 Website : www.shivamills.com
EXTRACT OF THE DETAILED FORMAT OF QUARTERLY/ HALF-YEARLY UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2022 FILED WITH STOCK EXCHANGES UNDER REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS 2015. (Rs.in lakhs Except earnings per share data)
Sl. No.	PARTICULARS	Quarter ended 30.09.2022 (Unaudited)	Quarter ended 30.09.2021 (Unaudited)	Half Year ended 30.09.2022 (Unaudited)	Half Year ended 30.09.2021 (Unaudited)
1.	Total Income from operations	4,495.58	5,381.88	8,991.09	9,015.44
2.	Net Profit/(Loss) for the period before Tax, Exceptional and/or Extraordinary items	(455.99)	648.07	28.67	1,174.45
3.	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(455.99)	648.07	28.67	1,174.45
4.	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	(331.31)	474.58	20.83	860.47
5.	Total Comprehensive Income for the period (Comprising Profit/ (Loss) for the period (after Tax) and other Comprehensive Income (after Tax)	(326.26)	472.53	30.93	856.37
6.	Equity Share Capital	864.18	864.18	864.18	864.18
7.	Earnings per Share (of Rs.10 each) (for continuing and discontinued operations) i) Basic ii) Diluted	(3.83) (3.83)	5.49 5.49	0.24 0.24	9.96 9.96
Notes 1) The full format of the quarterly financial results are available on the Stock Exchanges websites www.bseindia.com, www.nseindia. com and Company’s website www.shivamills.com 2) Previous period/year figures have been regrouped wherever necessary FOR SHIVA MILLS LIMITED S V ALAGAPPAN MANAGING DIRECTOR DIN 00002450 PLACE : COIMBATORE DATE : 12.11.2022

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

==> picture [427 x 417] intentionally omitted <==

----- Start of picture text -----

ASPIRA PATHLAB & DIAGNOSTICS LIMITED
CIN:- L85100MH1973PLC289209
Reg. Office : Flat No.2, R.D.Shah Building, Shraddhanand Road, Opp. Railway Station,
Ghatkopar (W.), Mumbai -400086 Tel No.: 71975656 ;
email ID: info@aspiradiagnostics.com ; website: www.aspiradiagnostics.com
Extract of Unaudited Financial Results for the quarter and half year ended September 30, 2022
(Rupees in Lakhs)
Quarter Ended Half Year Ended Year Ended
Sr Particulars
No 30.09.2022 30.06.2022 30.09.2021 30.09.2022 30.09.2021 31.03.2022
(Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited)
1. Total income from operations 377.57 303.19 351.39 680.76 941.99 1964.48
2. Net Profit / (Loss) for the period (before Tax,
Exceptional and /or Extraordinary items) 1.51 (28.52) 14.46 (27.01) 214.80 445.94
3. Net Profit / (Loss) for the period before tax
(after Exceptional and/or Extraordinary items) 1.51 (28.52) 14.46 (27.01) 214.80 445.94
4. Net Profit / (Loss) for the period after tax
(after Exceptional and/or Extraordinary items) 1.51 (28.52) 14.46 (27.01) 214.80 445.94
5. Total Comprehensive Income for the period
(Comprising profit/(loss) for the period(after tax)
and other Comprehensive Income(after tax) 1.51 (28.52) 14.46 (27.01) 214.80 447.49
6. Equity Share Capital 1029.30 1029.30 1029.30 1029.30 1029.30 1029.30
7. Reserves (excluding Revaluation Reserve)
as shown in the Audited Balance Sheet of
previous year) - - - - - -
8. Earnings Per Share (of ?10/- each)
(for continuing and discontinued operations) -
Basic: 0.01 (0.28) 0.14 (0.26) 2.09 4.33
Diluted: 0.01 (0.28) 0.14 (0.26) 2.09 4.33
Note:
a. The above is an extract of the detailed format of Un-Audited Financial Results for the quarter and half year ended September
30, 2022, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements)
Regulations, 2015. The full format of the Financial Results for the quarter and half year ended September 30, 2022 is available
on the websites of the Stock Exchange(s) and the company's website:- www.aspiradiagnostics.com.
b. The above result has been reviewed by the Audit Committee and approved by Board of Directors at their meeting held on
November 12, 2022.
For and on behalf of the Board
For Aspira Pathlab & Diagnostics Limited
Sd/-
Dr. Pankaj Shah
Place:- Mumbai Managing Director
Date:- November 12, 2022 DIN: 02836324
----- End of picture text -----

AUROBINDO PHARMA LIMITED

( CIN - L24239TG1986PLC015190) Regd. Office: Plot No.2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India. Tel: +91 040 23736370 Fax: +91 40 23747340 Email: info@aurobindo.com STATEMENT OF STANDALONE / CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2022

==> picture [418 x 346] intentionally omitted <==

----- Start of picture text -----

(All amounts are in ₹ in millions, unless otherwise stated)
Standalone Consolidated
Quarter Half Year Quarter Quarter Half Year Quarter
Sr. Particulars ended ended ended ended ended ended
No.
30.09.2022 30.09.2022 30.09.2021 30.09.2022 30.09.2022 30.09.2021
Unaudited Audited Unaudited Unaudited Audited Unaudited
1 Total income from operations (net) 30,256.6 58,125.8 28,831.8 57,393.7 1,19,752.9 59,419.2
2 Net Profit for the period 2,237.6 3,938.3 3,204.8 5,233.6 12,023.5 9,676.2
(before Tax and Exceptional items)
3 Net Profit for the period before tax 2,237.6 3,938.3 3,204.8 5,233.6 12,023.5 9,676.2
(after Exceptional items)
4 Net Profit for the period after tax 1,646.3 2,867.9 1,976.8 4,103.7 9,307.5 6,967.1
(after Exceptional items)
5 Total Comprehensive income for the 1,675.6 2,901.4 1,976.7 4,792.3 11,766.7 5,745.8
period [Comprising Profit for the period
(after tax) and Other Comprehensive
income (after tax)]
6 Paid-up equity Share Capital 585.9 585.9 585.9 585.9 585.9 585.9
(face value of ₹ 1/- each)
7 Other equity (excluding Revaluation 1,70,852.2 2,54,694.7
Reserve) as shown in the unaudited
financial results
8 Other equity (excluding Revaluation As on March 31, 2022 As on March 31, 2022
Reserve) as shown in the Audited Balance 170,587.5 245,173.9
Sheet of previous year
9 Earnings per share of ₹ 1/- each (Not annualised) (Annualised) (Not annualised) (Not annualised) (Annualised) (Not annualised)
(a) Basic (in ₹) 2.81 4.89 3.37 6.99 15.87 11.89
(b) Diluted (in ₹) 2.81 4.89 3.37 6.99 15.87 11.89
Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing
obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchanges’ web sites
viz. www.bseindia.com, www.nseindia.com and on the Company’s web site viz. www.aurobindo.com
By Order of the Board
Aurobindo Pharma Limited
Sd/-
Place : Hyderabad K. Nithyananda Reddy
Date : November 12, 2022 Vice Chairman & Managing Director
----- End of picture text -----

==> picture [474 x 1407] intentionally omitted <==

www.aurobindo.com

13

नईदिल्ी | सोमवार, 14 नवंबर2022

==> picture [936 x 767] intentionally omitted <==

==> picture [304 x 199] intentionally omitted <==

----- Start of picture text -----

Vfbdð´fÂf chMZlsy fyfeVsM
´fi´fÂf ªfe lhvkbZ,u ua- L65991TN1936PLC001428
(WX³fba¦fd»fE MÐX½ffg¹fªf÷Yd¨f IYeE¯OXAd·f½¹fd¢°fMZX¢ÀfMXfB»ÀfWZX°fb Af¸f³Âf¯f)d»fd¸fMZXOX IZY Qksu% 91&44&2829iath—r3296 A bZesy%dk;kZy;%ho@beardsell.co.in47 xzhEl jksM] ApsUubZ&600006osclkbV% www.beardsell.co.in
IÈ ´f¹ff 10.11.2022 I û d¶fdªf³fZÀf ÀM¯OOÊ lkoZtfud lwpuk<br>(Àf·fe ÀfaÀI S¯f) ¸fZÔ ´fiI fdVf°f ´fi´fÂf ªfe I f Àf³Q·fÊ »fZÔÜ ,rn~}kjk lwfpr fd;k tkrk gS fd Hkkjrh; izfrHkwfr vkSj fofue; cksMZ<br>´fi´fÂf ªfe IZ d³f¦fʸf³f I e d°fd±f 09.11.2022 IZ ¶fªff¹f ¼bfDoVh 'ks;jksa dh fMfyfLVax½ fu;eu] 2021 ds [kaM 5 o 6 ds vuqikyu<br>07.11.2022 WÜ esa “kqØokj] 12 vxLr] 2022 dks vk;ksftr viuh cSBd esa daiuh ds
IÈY°fZ WX³fba¦f MÐX½ffg¹fªf E¯OX MZX¢ÀfMXfB»Àf d»fd¸fMZXOX funs”kd eaMy us “ks;j/kkjdksa dks fcuk dksbZ fuxZe volj fn,
WX./- ch,lbZ fyfeVsM ¼ch,lbZ½ ls daiuh ds bfDoVh “ks;jksa dks LoSfPNd
AVfûIY IbY¸ffSX ¦fb´°ff vlwphc) djus dk izLrko vuqeksfnr dj fn;k gSA daiuh ch,lbZ ls
Àf¸ff²ff³f ´fiûRZYVf³f»f vius bfDoVh “ks;jksa dks LoSfPNd vlwphc) djus ds fy, vkosnu djus
´faªfeIYSX¯f Àfa. : IBBI/IPA-003/IP-N00010/2016-2017/10072 dh izfØ;k esa gSA
vlwphc)rk dh vko”;drk vkSj mn~ns”;%
bfDoVh “ks;jksa dk izLrkfor vlwphc)dj.k iz”kklfud lqfo/kk vkSj
lwphc)rk ds laca/k esa vuqikyu ykxr dks ;qfDrlaxr djus dh ,d
dok;n gSA daiuh ds bfDoVh “ks;jksa dh us”kuy LVkWd ,Dlpsat vkWQ
bafM;k fy- ¼,u,lbZ½ ftuds VªsfMax VehZuyksa dk ns”kO;kih vkSj lqfoLr`r
usVodZ gS] esa lwphc)rk tkjh jgsxh vkSj ch,lbZ ls bfDoVh “ks;jksa dh
vlwphc)rk ls fuos”kdksa ij dksbZ izfrdwy izHkko ugha iM+sxkA
fgrs chMZlsy fyfeVsM
LFkku % psUubZ dkUgw pj.k lkgw
fnukad% 10-11-2022 daiuh lfpo
----- End of picture text -----